Trastuzumab deruxtecan for treated HER2-low advanced breast cancer
Article Sidebar
Main Article Content
Abstract
Breast cancer is the most prevalent cancer diagnosis and is the second leading cause of cancer-related deaths in women. Patients with HER2 protein overexpression or HER2 positive status benefit from HER2 inhibitors, including those with HER2 low breast cancer, Trastuzumab deruxtecan, classified as HER2-directed antibody drug conjugates (ADCs), deliver cytotoxic agents to cancer cells. Trastuzumab deruxtecan is FDA-approved for adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy. The recommended dose is 5.4 mg/kg given intravenously every 3 weeks.Common adverse reactions include nausea, vomiting, decreased appetite and anemia.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
บทความทีตีพิมพ์ในวารสารโรคมะเร็งนี้ถือว่าเป็นลิขสิทธิ์ของมูลนิธิสถาบันมะเร็งแห่งชาติ และผลงานวิชาการหรือวิจัยของคณะผู้เขียน ไม่ใช่ความคิดเห็นของบรรณาธิการหรือผู้จัดทํา
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209-49.
National Comprehensive Cancer Network (NCCN) Guidelines. Breast Cancer (version4. 2022) [Internet]. [cited 2023 Mar 30]. Available from: http://www.nccn.org/ professionals/physician_ gls/pdf/breast.pdf.
เรวัต พันธุ์วิเชียร. Genomics & Targeted Therapy of Breast cancers. พิมพ์ครั้งที่ 1. กรุงเทพ: ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ โรงพยาบาลรามาธิบดี มหาวิทยาลัยมหิดล, 2565
Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-Low Breast Cancer: Pathological and Clinical Landscape. J Clin Oncol. 2020;38:1951-62.
หน่วยคลังข้อมูลยา คณะเภสัชศาสตร์ มหาวิทยาลัยมหิดล. (2564). Margetuximab anti-HER2 antibody ชนิดใหม่สำหรับรักษาโรคมะเร็งเต้านม.
Nguyen X, Hooper M, Borlagdan JP, et al. A Review of Fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Breast Cancer. Ann Pharmacother. 2021;55:1410-8.
Abuhelwa Z, Alloghbi A, Nagasaka M. A comprehensive review on antibody-drug conjugates (ADCs) in the treatment landscape of non-small cell lung cancer (NSCLC). Cancer Treat Rev. 2022;106:102393.
Enhertu. Package insert. Daiichi Sankyo Co; 2019.
Azar I, Alkassis S, Fukui J, Alsawah F, Fedak K, Al Hallak MN, et al. Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. Lung Cancer Auckl. 2021;12:103-14.
Ogitani Y, Hagihara K, Oitate M, Naito H, Agatsuma T. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107:1039-46.
Shitara K, Baba E, Fujitani K, Oki E, Fujii S, Yamaguchi K. Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer. Gastric Cancer. 2021;24:780-9.
Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387:9-20.
Tamura K, Tsurutani J, Takahashi S, et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol. 2019;20:816-26.
